Hyloris Pharmaceuticals S.A. (HYL.BR)
Hyloris Pharmaceuticals S.A. operates in the Biotechnology industry of the Healthcare sector, headquartered in Liège, WA, BE. The stock last traded at $4.70, up 4.44% on the session, giving a market capitalisation of $131.6M. Its beta of 0.65 implies it has historically moved less than the broad market.
Hyloris Pharmaceuticals SA is dedicated to developing, manufacturing, and bringing to market pharmaceutical products designed to fulfill critical unmet medical needs. The company's focus areas include cardiovascular health, oncology, women's health, and other significant therapeutic domains. Its cardiovascular portfolio features treatments for conditions such as atrial fibrillation, acute coronary syndrome, advanced and congestive heart failure, and coronary heart disease. Beyond this, Hyloris addresses a diverse range of other ailments, including post-operative pain management, dental indications, severe and recurring vulvovaginal candidiasis, specific cancers (like acute myeloid leukemia and small cell lung cancer), interstitial cystitis/painful bladder syndrome (IC/PBS), attention deficit hyperactivity disorder (ADHD), and various viral infections. Established in 2012, Hyloris Pharmaceuticals SA is headquartered in Liège, Belgium.
Hyloris Pharmaceuticals S.A. is most often compared with the following Healthcare names: